Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | TNKS | O95271 | 1/20 | 0.43 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1733527 | 0.84 | SMN1; SMN2 (0.54) | TDP1MAPTLMNAKMT2AALDH1A1 | |
| SCHEMBL30002312 | 0.84 | SMN1; SMN2 (0.54) | TDP1MAPTLMNAKMT2AALDH1A1 | |
| SCHEMBL2906705 | 0.83 | MAPT (0.49) | TDP1MAPTKMT2ASLC6A2SLC6A3 | |
| SCHEMBL8562941 | 0.80 | MAPT (0.57) | TDP1MAPTLMNAKMT2ASLC6A2 | |
| SCHEMBL561686 | 0.79 | KDM4E (0.54) | MAPTLMNAKMT2AALDH1A1KDM4E | |
| SCHEMBL31389316 | 0.79 | KDM4E (0.54) | MAPTLMNAKMT2AALDH1A1KDM4E | |
| SCHEMBL8403275 | 0.78 | MAPT (0.79) | TDP1MAPTKMT2ASLC6A2SLC6A3 | |
| SCHEMBL18118665 | 0.77 | KMT2A (0.56) | TDP1MAPTLMNAKMT2ASLC6A2 | |
| SCHEMBL6616258 | 0.77 | KMT2A (0.60) | TDP1MAPTLMNAKMT2ASLC6A2 | |
| Transtorine SCHEMBL22979 | 0.76 | ALOX15 (0.60) | TDP1MAPTLMNAALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020077491-A1 | Methods for forming combinatorial libraries combining amide bond formation with epoxide opening | NEOGENESIS PHARMACEUTICALS, INC. | 2002-06-20 | — | — | US | disclosed |
| WO-2002020436-A2 | METHODS FOR FORMING COMBINATORIAL LIBRARIES COMBINING AMIDE BOND FORMATION WITH EPOXIDE OPENING | NEOGENESIS PHARMACEUTICALS, INC. (US) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077491-A1 | Methods for forming combinatorial libraries combining amide bond formation with epoxide opening | EPHX2, COASY, EPHX1 | TDP1 3552/4885MAPT 3620/4885LMNA 4655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.